| Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function. | |
| | |
MedLine Citation:
|
PMID: 17270296 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The EUROPA trial has demonstrated that an ACE inhibitor perindopril, was able to significantly decrease the risk of major cardiac events in patients with stable coronary heart disease without apparent heart failure. AIM: To assess the long-term clinical outcome of patients with stable coronary heart disease and preserved left ventricular function (left ventricular ejection fraction (LVEF> or =40%). METHODS: A retrospective evaluation of LVEF was performed in the EUROPA study population. Among the 12,218 patients of EUROPA, we identified 7096 (58%) patients who had LVEF measurement before randomization. The measurements were obtained mainly by echocardiography in 5214 cases (73%) or by angiography in 1470 cases (21%). Two groups of patients were studied: 6878 (97 %) patients with LVEF> or =40% (3429 received 8 mg of perindopril and 3449 received a placebo) and 218 patients (3%) with a LVEF<40% (111 received perindopril and 107 a placebo). RESULTS: The baseline characteristics of patients with documented LVEF were similar to the whole EUROPA population in terms of demographics, medical history, physical examination (heart rate, blood pressure), and medications at screening. The mean LVEF of this population was 57.0+/-10.4%. In patients (n=6878) with preserved LV function (LVEF> or =40%), there was a significant relative risk reduction of 16% of the primary endpoint (a composite of cardiovascular death, non-fatal myocardial infarction and resuscitated cardiac arrest) in the group treated with perindopril (8.3%) in comparison to the group treated with placebo (9.8%): Hazard ratio (HR)=0.84 [95% CI: 0.72-0.99] p=0.033). Similar results were obtained for the first secondary endpoint (total mortality, non-fatal myocardial infarction, hospital admission for unstable angina and cardiac arrest with successful resuscitation): HR=0.85 [95% CI: 0.76-0.96] p=0.008, for cardiovascular mortality and non-fatal MI: HR=0.84 [95% CI: 0.72-0.99] p=0.036. Similar benefits were observed in patients with an LVEF> or =40% and a history of previous myocardial infarction and in patients with an LVEF<40%. CONCLUSIONS: LVEF was documented in 58% of the EUROPA study population and only 3% had an impaired LV function, confirming that EUROPA patients did not have asymptomatic LV dysfunction. Results in patients with preserved LV function are consistent with those of the whole EUROPA study population and perindopril 8 mg is beneficial in the broad spectrum of patients with stable coronary artery disease without evidence of heart failure. |
| | |
Authors:
|
Michel E Bertrand; Willem J Remme; Kim M Fox; Roberto Ferrari; Maarten L Simoons; |
Related Documents
:
|
16209986 - Sirolimus-eluting stent implantation in diabetic patients with multivessel coronary art... 20664026 - Do major cardiovascular outcomes in patients with stable ischemic heart disease in the ... 16490816 - Renal function and outcome from coronary artery bypass grafting: impact on mortality af... 18328836 - Usefulness of noninvasive estimate of pulmonary vascular resistance to predict mortalit... 7707036 - Early management of acute myocardial ischemic events. recommendations. quality of patie... 10994936 - Intravascular physiologic evaluation of the left anterior small thoracotomy operation: ... |
Publication Detail:
|
Type: Journal Article Date: 2007-01-31 |
Journal Detail:
|
Title: International journal of cardiology Volume: 121 ISSN: 1874-1754 ISO Abbreviation: Int. J. Cardiol. Publication Date: 2007 Sep |
Date Detail:
|
Created Date: 2007-08-27 Completed Date: 2007-09-28 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8200291 Medline TA: Int J Cardiol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 57-61 Citation Subset: IM |
Affiliation:
|
Lille Heart Institute, Lille, France. mbertrand@cardiolille.net <mbertrand@cardiolille.net> |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin-Converting Enzyme Inhibitors
/
therapeutic use* Coronary Artery Disease / drug therapy*, mortality Female Heart Arrest / epidemiology, prevention & control Humans Male Middle Aged Myocardial Infarction / epidemiology, prevention & control Outcome Assessment (Health Care) Perindopril / therapeutic use* Randomized Controlled Trials as Topic Retrospective Studies Stroke Volume / physiology Ventricular Function, Left / physiology* |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 82834-16-0/Perindopril |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Nuclear factor-kappaB activity in peripheral blood mononuclear cells in cachectic and non-cachectic ...
Next Document: Elevated high sensitivity CRP levels in patients with mitral stenosis and left atrial thrombus.